Protox Therapeutics Inc. (TSX: PRX), a leader in the development of receptor targeted fusion proteins, today announced that two oral podium presentations on the company's lead candidate, PRX302, will be made at the 2010 Annual Meeting of the American Urological Association (AUA). These presentations will include six month data from the Phase 2b clinical study of PRX302 called TRIUMPH, in patients with moderate to severe benign prostatic hyperplasia (BPH). The annual AUA meeting is the world's largest gathering of urology professionals and takes place May 29 - June 3 at the Moscone Convention Center in San Francisco, California.
Dr. Mostafa M. Elhilali, OC, M.D., Ph.D. Chief Co-Principal Investigator and Stephen Jarislowsky Chair of Urology at McGill University, will deliver both podium presentations on Tuesday, June 1, 2010 as follows:
Session: Late-Breaking Science Forum Title: Results of a Phase IIb Double-Blinded Placebo-Controlled Study of Transperineal Intraprostatic Injection of a PSA-Activated Protoxin (PRX 302) in Patients with Moderate to Severe LUTS Location, Date and Time: Moscone South, Room 103, Tuesday, June 1, 2010, 1:00 PM (PST) Session: Benign Prostatic Hyperplasia; Medical and Hormonal Therapy Title: Evaluation of Transperineal Prostatic Administration of a PSA activated Protoxin (PRX302) in Men with LUTS secondary to BPH Location, Date and Time: Moscone North Building, Room 120, Podium 52, Tuesday, June 1, 2010, 3:30 PM (PST)
A new era of targeted therapy with antibody–drug conjugates